Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort

Show simple item record

dc.contributor.author Dodgen, Tyren Mark
dc.contributor.author Drögemöller, Britt I.
dc.contributor.author Wright, Galen E.B.
dc.contributor.author Warnich, Louise
dc.contributor.author Steffens, Francois E.
dc.contributor.author Cromarty, Allan Duncan
dc.contributor.author Alessandrini, Marco
dc.contributor.author Pepper, Michael Sean
dc.date.accessioned 2015-10-30T07:50:55Z
dc.date.issued 2015-08
dc.description.abstract AIM : To align predicted and measured CYP2C19 phenotype in a South African cohort. MATERIALS AND METHODS : Genotyping of CYP2C19*2, *3, *9, *15, *17, *27 and *28 was performed using PCR-RFLP, and an Activity Score (AS) system was used to predict phenotype.True phenotype was measured using plasma concentrations of omeprazole and its metabolite 5’-hydroxyomperazole. RESULTS : Partial genotype-phenotype discrepancies were reported, and an adapted AS system was developed, which showed a marked improvement in phenotype prediction. Results highlight the need for a more comprehensive CYP2C19 genotyping approach to improve prediction of omeprazole metabolism. CONCLUSION : Evidence for the utility of a CYP2C19 AS system is provided, for which the accuracy can be further improved by means of comprehensive genotyping and substrate specific modification. en_ZA
dc.description.embargo 2016-08-31
dc.description.librarian hb2015 en_ZA
dc.description.sponsorship Departments of Pharmacology and Immunology, University of Pretoria; the National Research Foundation of South Africa (NRF) grant numbers FA2006032700005 and TK2006051500005; the National Health Laboratory Services of South Africa (NHLS); the South African Medical Research Council (SAMRC) Extramural Unit for Inflammation and Immunity, and Ampath Laboratories, South Africa. en_ZA
dc.description.uri http://www.futuremedicine.com/loi/pgs en_ZA
dc.identifier.citation Dodgen, TM, Drögemöller, BI, Wright, GEB, Warnich, L, Steffens, FE, Cromarty, AD, Alessandrini, M & Pepper, MS 2015, 'Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort', Pharmacogenomics, vol. 16, no. 12, pp. 1343-1354. en_ZA
dc.identifier.issn 1462-2416 (print)
dc.identifier.issn 1744-8042 (online)
dc.identifier.other 10.2217/pgs.15.80
dc.identifier.uri http://hdl.handle.net/2263/50280
dc.language.iso en en_ZA
dc.publisher Future Medicine en_ZA
dc.rights Future Medicine en_ZA
dc.subject CYP2C19 en_ZA
dc.subject Oomeprazole en_ZA
dc.subject Activity score system en_ZA
dc.subject Genotype-phenotype correlation en_ZA
dc.subject South Africa (SA) en_ZA
dc.title Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record